FY2027 EPS Estimate for Boston Scientific Boosted by Analyst

Key Points

• Analyst Upgrade: Leerink Partners raised their FY2027 EPS estimate for Boston Scientific to $3.97 from $3.93, maintaining a "Strong-Buy" rating for the stock.
• Recent Earnings Performance: Boston Scientific exceeded earnings expectations for Q2, reporting $0.75 EPS against a consensus of $0.72, with revenues reaching $5.06 billion.
• Institutional Interest: A significant 89.07% of Boston Scientific's stock is owned by institutional investors, indicating strong confidence in the company's future.

Boston Scientific Corporation (NYSE:BSX - Free Report) - Equities researchers at Leerink Partnrs upped their FY2027 earnings estimates for shares of Boston Scientific in a report issued on Wednesday, October 1st. Leerink Partnrs analyst M. Kratky now anticipates that the medical equipment provider will post earnings per share of $3.97 for the year, up from their previous estimate of $3.93. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Boston Scientific's current full-year earnings is $2.85 per share. Leerink Partnrs also issued estimates for Boston Scientific's FY2028 earnings at $4.49 EPS and FY2029 earnings at $5.06 EPS.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business's quarterly revenue was up 22.8% compared to the same quarter last year. During the same period last year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS.

A number of other brokerages have also commented on BSX. Canaccord Genuity Group boosted their price objective on Boston Scientific from $131.00 to $132.00 and gave the stock a "buy" rating in a report on Wednesday. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $125.00 target price on shares of Boston Scientific in a research report on Monday. UBS Group increased their price target on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research report on Thursday, July 24th. BTIG Research raised their price objective on Boston Scientific from $127.00 to $132.00 and gave the company a "buy" rating in a research note on Wednesday. Finally, Robert W. Baird upped their target price on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an "outperform" rating in a research note on Wednesday. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $120.79.

Boston Scientific Trading Up 0.5%

BSX opened at $96.36 on Friday. Boston Scientific has a fifty-two week low of $80.64 and a fifty-two week high of $109.50. The firm has a market capitalization of $142.78 billion, a PE ratio of 57.36, a P/E/G ratio of 2.31 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company's 50-day moving average is $103.10 and its 200 day moving average is $102.06.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company's stock, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock valued at $17,972,457 over the last quarter. Corporate insiders own 0.50% of the company's stock.

Hedge Funds Weigh In On Boston Scientific

Institutional investors and hedge funds have recently bought and sold shares of the company. 1248 Management LLC bought a new stake in shares of Boston Scientific in the first quarter valued at $26,000. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth about $26,000. Y.D. More Investments Ltd bought a new stake in Boston Scientific in the 1st quarter valued at about $27,000. Sound Income Strategies LLC lifted its holdings in Boston Scientific by 90.9% during the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider's stock valued at $27,000 after purchasing an additional 120 shares during the last quarter. Finally, Kilter Group LLC bought a new position in Boston Scientific during the second quarter worth about $30,000. 89.07% of the stock is owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.